Normorphinan N-Alkylation via Formic Acid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing N-alkylated morphinans rely on expensive and toxic transition metal catalysts and hazardous hydrogen gas, posing safety and efficiency concerns, and often require complex purification processes.
Innovation Solution
A process involving the reaction of normorphinan with an alkylating agent and a reducing agent such as formic acid or methyl formate to form N-alkylated morphinans, eliminating the need for transition metal catalysts and hydrogen gas, and allowing for a one-pot synthesis without intermediate isolation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If transition metal catalysts are used for N-alkylation, then the reaction can proceed efficiently, but the product contains toxic metal residues requiring costly purification
Solution Approach 1:
The patent removes the harmful transition metal catalyst from the reaction system entirely, replacing it with a metal-free organocatalytic system using formic acid/methyl formate as both solvent and reducing agent, thereby eliminating toxic metal residues from the final product
Solution Approach 2:
The patent employs formic acid and methyl formate as inexpensive, readily available reagents that decompose into harmless byproducts (CO2, H2O, methanol), replacing expensive and persistent metal catalysts with disposable, environmentally benign alternatives
2Ease of manufacture
If hydrogen gas is used as hydrogen source, then reduction can be achieved, but safety hazards and high pressure requirements increase
Solution Approach 1:
The patent replaces hazardous hydrogen gas with formic acid and methyl formate, which are stable, non-flammable liquids that decompose safely under reaction conditions to provide the necessary reducing equivalents without requiring high pressure equipment
Solution Approach 2:
The patent changes the physical state and chemical form of the hydrogen source from gaseous H2 requiring high pressure to liquid/solid formic acid and methyl formate that can be handled under ambient or mild conditions, fundamentally altering the safety profile of the reduction step
3Manufacturing precision
If multiple synthesis steps are used, then product purity can be achieved, but process complexity and time increase
Solution Approach 1:
The patent combines multiple reaction steps (alkylation and reduction) into a single one-pot operation where formic acid or methyl formate serves dual functions as both solvent and reducing agent, eliminating the need for intermediate isolation and simplifying the overall process while maintaining product purity
Solution Approach 2:
The patent employs formic acid and methyl formate as multi-functional reagents that simultaneously serve as solvent, hydrogen source, and reaction medium for both alkylation and reduction steps, replacing multiple specialized reagents and simplifying the synthetic protocol
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides an efficient and cost-effective synthesis of N-alkylated morphinans with high yield, avoiding the use of toxic catalysts and hazardous gases, and simplifying the production process by eliminating the need for intermediate purification.
Implementation Method 1
contacting the compound comprising Formula (IIa) with a reducing agent selected from the group consisting of formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, and combinations thereof, to form a compound comprising Formula (IIIa)
Data Source
AI summary
The invention provides a process for the N-alkylation of normorphinan compounds to produce N-alkylated morphinan compounds. In particular, the process relates to the alkylation of a normorphinan compound by a carboxaldehyde in the presence of a reducing agent to form an N-alkylated morphinan.